journal article·2018-09-19

Design of an Amphiphilic iRGD Peptide and Self-Assembling Nanovesicles for Improving Tumor Accumulation and Penetration and the Photodynamic Efficacy of the Photosensitizer

Yue Jiang, Xin Pang, Ruiling Liu, Qicai Xiao, Pan Wang, Albert Wingnang Leung, Yuxia Luan, Chuanshan Xu

ACS Applied Materials & Interfaces· Volume 10· Issue 37
Publisher page

Abstract

Photodynamic therapy (PDT) is a minimally invasive treatment for many diseases, including infections and tumors. Nevertheless, clinical utilization of PDT is severely restricted due to the shortcomings of the photosensitizers, especially their low water solubility and poor tumor selectivity. iRGD (internalizing RGD, CRGDKGPDC), a nine-unit cyclic peptide, was applied as an active ligand to realize tumor homing and tissue penetration. Herein, we innovatively fabricated a novel OFF-ON mode iRGD-based peptide amphiphile (PA) to self-assemble into spherical nanovesicles to enhance the tumor-targeting and tumor-penetrating efficacy of PDT. To introduce the self-assembling feature into iRGD, a hydrophilic arginine-rich sequence and hydrophobic alkyl chains were sequentially linked to the iRGD motif. A short proline sequence was selected to control the morphology of the self-assembled aggregates. Next, the photosensitizer hypocrellin B (HB) was encapsulated into PA vesicles with a high loading efficiency. The aggregation-caused quenching effect inactivated HB in the PA vesicles; however, the iRGD-peptide-based material was able to be selectively degraded in tumor cells. Thus, the HB fluorescence was recovered to achieve tumor-targeted imaging. This approach endows HB-loaded PA vesicles (HB-PA) with tumor-targeted activation, preferable tumor accumulation, and deep tumor penetration, thus leading to an excellent fluorescence-imaging-guided photodynamic efficacy both in vitro and in vivo. These amphiphilic iRGD aggregates provide a novel strategy for improving the accumulation, penetration, and imaging-guided photodynamic efficacy of photosensitizers.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Photodynamic Therapy Research Studies · Luminescence and Fluorescent Materials

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Science, Shandong University, 44 West Wenhua Road, Jinan 250012, Shandong, P. R. China

School of Chinese Medicine, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong, P. R. China

Division of Chinese Medicine, School of Professional and Continuing Education, The University of Hong Kong, Hong Kong, P. R. China

Key Laboratory of Molecular Target and Clinical Pharmacology, School of Pharmaceutical Sciences & Fifth Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 511436, P. R. China

Funding

Health and Medical Research Fund · Research Grants Council, University Grants Committee

References (45)

Show source-provided references
1. Dougherty T. J. · Cancer Res. · 1978 · 38 · 2628
2. 10.1038/nrc107110.1038/nrc1071 ↗
3. 10.1111/j.1751-1097.2011.00986.x10.1111/j.1751-1097.2011.00986.x ↗
4. 10.1002/lsm.2063210.1002/lsm.20632 ↗
5. 10.1016/j.pdpdt.2017.07.00210.1016/j.pdpdt.2017.07.002 ↗
6. 10.1021/cr900236h10.1021/cr900236h ↗
7. 10.3322/caac.2011410.3322/caac.20114 ↗
8. 10.1039/c3cs60036j10.1039/c3cs60036j ↗
9. 10.1002/adma.20170535010.1002/adma.201705350 ↗
10. 10.1021/acsami.6b1157910.1021/acsami.6b11579 ↗
11. 10.1021/acsbiomaterials.7b0064810.1021/acsbiomaterials.7b00648 ↗
12. 10.1039/C5NR07785K10.1039/C5NR07785K ↗
13. 10.1021/acsnano.6b0668810.1021/acsnano.6b06688 ↗
14. 10.1021/jacs.6b0487510.1021/jacs.6b04875 ↗
15. 10.1021/jacs.7b0591610.1021/jacs.7b05916 ↗
16. 10.1039/B915149B10.1039/B915149B ↗
17. 10.1038/nrc145610.1038/nrc1456 ↗
18. 10.1002/adma.20150150210.1002/adma.201501502 ↗
19. 10.1021/mp300273310.1021/mp3002733 ↗
20. 10.1083/jcb.20091010410.1083/jcb.200910104 ↗
21. 10.1158/0008-5472.CAN-12-166810.1158/0008-5472.CAN-12-1668 ↗
22. 10.1016/j.ccr.2009.10.01310.1016/j.ccr.2009.10.013 ↗
23. 10.1021/acsami.5b0939110.1021/acsami.5b09391 ↗
24. 10.1002/adfm.20150478010.1002/adfm.201504780 ↗
25. 10.1002/adhm.20160016010.1002/adhm.201600160 ↗
26. 10.1021/acsnano.6b0873110.1021/acsnano.6b08731 ↗
27. 10.1080/1061186X.2016.123809110.1080/1061186X.2016.1238091 ↗
28. 10.1073/pnas.07206559910.1073/pnas.072065599 ↗
29. 10.1039/c2cs35115c10.1039/c2cs35115c ↗
30. 10.1002/adfm.20160539710.1002/adfm.201605397 ↗
31. 10.1021/nl202220q10.1021/nl202220q ↗
32. 10.1126/science.107497210.1126/science.1074972 ↗
33. 10.1002/anie.20070273210.1002/anie.200702732 ↗
34. 10.1038/nnano.2011.16610.1038/nnano.2011.166 ↗
35. 10.1021/acsami.6b1380810.1021/acsami.6b13808 ↗
36. 10.1021/acsami.6b0652210.1021/acsami.6b06522 ↗
37. 10.1039/C6TB02860H10.1039/C6TB02860H ↗
38. 10.1038/nrc189310.1038/nrc1893 ↗
39. 10.1038/ncomms1405610.1038/ncomms14056 ↗
40. 10.1016/j.jconrel.2017.12.00510.1016/j.jconrel.2017.12.005 ↗
41. 10.1016/j.biomaterials.2014.06.04210.1016/j.biomaterials.2014.06.042 ↗
42. 10.1021/cr500419810.1021/cr5004198 ↗
43. 10.1016/j.addr.2012.08.01110.1016/j.addr.2012.08.011 ↗
44. 10.1002/adfm.20160631410.1002/adfm.201606314 ↗
45. 10.1016/j.drudis.2017.04.01010.1016/j.drudis.2017.04.010 ↗